Tag Archives: intellectual property

Part II – Mayo’s Brief Goes Back to A (Non-Precedential) Past

Posted on November 7, 2011 by Warren Woessner

In my last post on Mayo v. Prometheus, I noted that Mayo is cutting a trail of (legal) tears to ultimately rely on the reasoning underlying the “LabCorp dissent” (548 U.S. 132, 136). In this dissent from a dismissal of … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged intellectual property, Mayo v Prometheus, Supreme Court, Warren Woessner | 1 Comment

EPO Ruling On Inventiveness Of Drug Polymorphs

Posted on November 5, 2011 by Warren Woessner

Thank you to Dr. Stefan Danner, a German and European Patent Attorney at DHS Patentanwaltsgesellschaft mbH in Munich for letting us post the current issue of the biotech IP newsletter dealing with the recent EPO decision concerning the patentability of … Continue reading →

Posted in EP and UK Practice | Tagged biotech, biotechnology law, biotechnology news, Dr. Stefan Danner, EPO, intellectual property, ip, Patent Law, polymorphs, T777/08, Warren Woessner | Leave a comment

Mayo’s Brief Goes Back To A (Non-Precedential) Future

Posted on November 3, 2011 by Warren Woessner

You all may be suffering from Prometheus v. Mayo fatigue by now, but this remains the most important IP case before the Supreme Court, and may well alter the course of life sciences patenting for the foreseeable future. I know … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged Federal Circuit, intellectual property, ip, Prometheus v. Mayo, Supreme Court, Warren Woessner | 1 Comment

Infringement by Unobvious Changes – A Look (Way) Back

Posted on October 16, 2011 by Warren Woessner

As a much younger attorney, I gave a presentation at the 1990 AIPLA Annual Meeting: “A Review of Recent Federal Circuit Decisions Relating to Infringement” (AIPLA Selected Legal Papers, 9, 3 (July 1991)), in which I wrestled with the question … Continue reading →